Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Aljian Capital Management LLC

Aljian Capital Management LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 398.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,052 shares of the medical research company’s stock after purchasing an additional 4,837 shares during the period. Amgen comprises about 0.5% of Aljian Capital Management LLC’s investment portfolio, making the stock its 29th biggest holding. Aljian Capital Management LLC’s holdings in Amgen were worth $1,950,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the 3rd quarter valued at about $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter valued at approximately $26,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $31,000. Finally, Bbjs Financial Advisors LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. TD Cowen upped their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. UBS Group dropped their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and lifted their price objective for the company from $320.00 to $333.00 in a research report on Monday, October 14th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $333.57.

Amgen Price Performance

NASDAQ AMGN opened at $283.61 on Monday. The stock has a market capitalization of $152.45 billion, a P/E ratio of 36.31, a P/E/G ratio of 2.53 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The business’s fifty day moving average is $320.85 and its two-hundred day moving average is $318.65. Amgen Inc. has a 1 year low of $260.52 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, research analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.